Abstract CT225: ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Aditya Bardia, Virginia Kaklamani, Joyce O’Shaughnessy, Peter Schmid, J. Thaddeus Beck, Michelino De Laurentiis, Giuseppe Curigliano, Hope S. Rugo, Carlos H. Barcenas, William J. Gradishar, Michail Ignatiadis, David A. Cameron, Giulia Tonini, Simona Scartoni, Jennifer Crozier, Tomer Wasserman, Sara M. Tolaney
Institutions: University of California, Los Angeles, UCLA Health, UCLA Jonsson Comprehensive Cancer Center, The University of Texas at San Antonio Health Science Center, Queen Mary University of London, Barts Cancer Institute, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Milan, European Institute of Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Université Libre de Bruxelles, Institut Jules Bordet, Institute of Genetics and Cancer, University of Edinburgh, Menarini Group (Italy), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409821706